Skip to main content


Figure 8 | Arthritis Research & Therapy

Figure 8

From: Suppressive effect of secretory phospholipase A2inhibitory peptide on interleukin-1β-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice

Figure 8

Serum levels of murine sPLA2 and IL-6, and human TNF-α. Tg197 mice received either vehicle (0.5% dimethyl sulfoxide in phosphate-buffered saline), peptides (P-NT.II or PIP-18), or comparator drugs (antiflammin-2, methotrexate, celecoxib and infliximab) at age three weeks (disease onset), and blood samples collected by cardiac puncture at termination (age eight weeks). Murine (m) serum secretory phospholipase A2 (sPLA2) levels were measured with an Escherichia coli membrane assay. Analysis of murine TNF-α and IL-6 was done by ELISA. Values are the mean ± standard error of the mean of each group; *P < 0.05; **P < 0.01 vs untreated or vehicle treated Tg197 mice.

Back to article page